Research Centre for Residue and Quality Analysis, FoH, SKUAST-Kashmir, Shalimar, Srinagar, 190025, Jammu & Kashmir, India.
Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, 641021, Tamil Nadu, India.
J Mol Model. 2023 May 31;29(6):192. doi: 10.1007/s00894-023-05603-7.
Inflammation-provoked disorders including cancer are arbitrated by cyclooxygenase-2 (COX-2). Celecoxib and niflumic acid are among the potent and selective inhibitors of this enzyme while aspirin (acetylsalicylic acid) and sodium salicylate are its non-selective and lesser potent inhibitors. Despite these proven studies, the comparative structural study of these selective and non-selective molecules at atomistic scale in complex state with COX-2 that may answer this differential inhibitory behavior has not been accomplished spotlighting the imperative need of additional research in this area. Thus, this study was framed to provide a strong explanation for the enigma of higher inhibitory activity of celecoxib-niflumic acid duo in comparison to aspirin and sodium salicylate towards COX-2.
A contemporary approach including advanced molecular docking against COX2, molecular dynamics of receptor-ligand complexes, simulation-trajectory-backed MMGBSA for different time points, radius of gyration (Rg) calculations, and e-pharmacophores approach was employed to attain a rational conclusion.
Our findings demonstrated the higher binding affinity of celecoxib and niflumic acid over aspirin and sodium salicylate against COX-2. Although both selective and non-selective COX-2 inhibitors manifested nearly the same stability in the active site of this enzyme but the e-pharmocophoric features found in the case of selective inhibitors scored over non-selective ones. Thus, our findings excluded the differential stability to be the cause of stronger potency of selective inhibitors but attributed their potency to greater number of complementary features present in these inhibitors against the active site of inflammation engendering COX-2.
环氧化酶-2(COX-2)介导的炎症相关疾病包括癌症。塞来昔布和尼氟灭酸是该酶的强效和选择性抑制剂,而阿司匹林(乙酰水杨酸)和水杨酸钠是非选择性和效力较低的抑制剂。尽管有这些已证实的研究,但在与 COX-2 形成复合物的状态下,对这些选择性和非选择性分子进行原子尺度的比较结构研究,可能有助于解答这种差异抑制行为,然而这项研究尚未完成,突显了在该领域进行更多研究的必要性。因此,本研究旨在为塞来昔布-尼氟灭酸双药对 COX-2 的抑制活性高于阿司匹林和水杨酸钠这一谜团提供有力解释。
采用了包括针对 COX2 的高级分子对接、受体-配体复合物的分子动力学、不同时间点的模拟轨迹支持的 MMGBSA、回转半径(Rg)计算和 e-pharmacophores 方法的现代方法,以得出合理的结论。
我们的研究结果表明,塞来昔布和尼氟灭酸与 COX-2 的结合亲和力高于阿司匹林和水杨酸钠。虽然选择性和非选择性 COX-2 抑制剂在该酶的活性部位都表现出几乎相同的稳定性,但在选择性抑制剂的情况下发现的 e-pharmocophoric 特征优于非选择性抑制剂。因此,我们的研究结果排除了差异稳定性是选择性抑制剂效力更强的原因,而是将其效力归因于这些抑制剂针对炎症引发 COX-2 的活性部位存在更多互补特征。